Last reviewed · How we verify
Frusemide
Frusemide, marketed by Melbourne Health, is an established treatment for acute pulmonary edema. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity. The primary risk is the potential increase in competition following patent expiry.
At a glance
| Generic name | Frusemide |
|---|---|
| Also known as | Lasix, spironolactone, hydrochlorothiazide, Rosiglitazone |
| Sponsor | Melbourne Health |
| Target | ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Acute pulmonary edema
- Decompensated cardiac failure
- Edema
- Edema due to Hepatic Cirrhosis
- Hypertensive disorder
- Peripheral Edema due to Chronic Heart Failure
- Pulmonary Edema due to Chronic Heart Failure
Common side effects
Key clinical trials
- Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib (PHASE1)
- A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005) (PHASE1)
- A Protocol Based-Furosemide Stress Test to Evaluate Renal Recovery During Continuous Renal Replacement Therapy (PHASE4)
- Forebrain Electroneutral Transporters in Salt-sensitive Hypertension: an MRI Study (PHASE4)
- POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure (PHASE2, PHASE3)
- Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers (PHASE1)
- Empagliflozin in Acute Heart Failure (PHASE4)
- Comparison of the Effectiveness of Different Diuretic Therapies in the Management of Acute Heart Failure (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Frusemide CI brief — competitive landscape report
- Frusemide updates RSS · CI watch RSS
- Melbourne Health portfolio CI